Fierce BD&L Summit for Life Sciences

Despite the challenges of the past few years, 2021 saw a continued return to normal deal-making activity in the life sciences sector as pharma and biotech companies quickly adapted and readjusted their business goals leading to a reinvigorated marketplace ripe with new opportunities but also with new challenges and risks. Now is the ideal time for life sciences companies to capitalize on the innovation and investment opportunities in the industry and build a comprehensive business development strategy for 2022.

With so much at stake, it is essential for life science organizations to effectively assess the risks associated with a deal, explore innovative models and deal structures for working with strategic partners, collaborate with cross-functional partners to realize business synergies and develop processes for the efficient and optimal negotiation and closing of a transaction.

With this in mind, the 3rd Fierce BD&L Summit returns LIVE in 2022 bringing together key deal-makers and serving as an open forum for cross-functional business development, due diligence, finance, and legal teams to share valuable insights and actionable strategies on successfully sourcing and evaluating new opportunities, conducting due diligence, and structuring licensing agreements and M&A deals. This year’s conference features expanded networking opportunities along with two days of panels, case studies, and practical sessions across three critical topic areas – Business Development, Due Diligence, and Legal/IP.